Porton Advanced and Ascle Therapeutics have recently announced a strategic partnership, focusing on joint efforts in the development and production of NK cells. The collaboration extends to advancing innovation in gene and cell therapy, with a particular emphasis on accelerating the application of NK cells in areas such as cancer prevention, beauty, and anti-aging.
Porton Advanced is dedicated to providing comprehensive gene and cell therapy CDMO (Contract Development and Manufacturing Organization) services, spanning various domains such as plasmids, cell therapy, gene therapy, and mRNA therapy. Currently, the company has successfully supported clients in completing CMC (Chemistry, Manufacturing, and Controls) and global declaration services for multiple gene and cell therapy drugs.
Ascle Therapeutics specializes in groundbreaking immune cell therapy products, particularly in the NK/CAR-NK anti-tumor immune cell therapy drugs. The company has established a robust immune cell therapy research and production system, boasting three major technology platforms: universal CAR-NK, allogeneic NK/CAR-NK, and mRNA-LNP.
According to the partnership agreement, Porton Advanced will provide development, production, and declaration services in China for Ascle Therapeutics' NK cell project. This collaboration aims to bolster the application of NK cells in cancer prevention, anti-aging, and beauty.
Ascle Therapeutics, emphasized the significant impact of CAR-NK cell therapy on cancer treatment. This genetic engineering approach enhances NK cells' ability to identify and eliminate tumor cells while minimizing harm to normal cells. Dr. Li also highlighted the remarkable efficacy of NK cells in anti-aging, with a single dose showing substantial reduction in circulating senescent cells for an extended period.
Porton Advanced, expressed enthusiasm about the strategic partnership, emphasizing Ascle Therapeutics' deep expertise in the NK field. Porton Advanced, with its end-to-end gene and cell therapy CDMO platform, is well-equipped to provide crucial support for Ascle Therapeutics' NK cell projects. Dr. Wang highlighted Porton Advanced's advanced capabilities in process development, sterile drug production, and adherence to international production and inspection standards.
The partnership is expected to facilitate swift progress in Ascle Therapeutics' NK cell projects related to anti-aging, beauty, and cancer prevention, leveraging Porton Advanced's expertise and infrastructure.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!